Berenberg lifts CEMEX S.A.B. de C.V. [CX] price estimate. Who else is bullish?

CEMEX S.A.B. de C.V. [NYSE: CX] surged by $0.02 during the normal trading session on Tuesday and reaching a high of $4.56 during the day while it closed the day at $4.55. The company report on August 2, 2022 that Cemex Takes Action to Reduce Road Transportation CO2 Emissions.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


CEMEX is replacing 200 diesel-powered trucks with gas-powered trucks in the Americas.

CEMEX S.A.B. de C.V. stock has also gained 6.06% of its value over the past 7 days. However, CX stock has inclined by 4.12% in the 3 months of the year. Over the past six months meanwhile, it has lost -15.90% and lost -32.89% year-on date.

The market cap for CX stock reached $6.57 billion, with 1.45 billion shares outstanding and 461.45 million shares in the current float. Compared to the average trading volume of 6.19M shares, CX reached a trading volume of 5249898 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about CEMEX S.A.B. de C.V. [CX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CX shares is $7.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Berenberg have made an estimate for CEMEX S.A.B. de C.V. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 10, 2022. The new note on the price target was released on April 20, 2022, representing the official price target for CEMEX S.A.B. de C.V. stock. Previously, the target price had yet another drop from $9.20 to $6, while Goldman kept a Neutral rating on CX stock.

The Average True Range (ATR) for CEMEX S.A.B. de C.V. is set at 0.16, with the Price to Sales ratio for CX stock in the period of the last 12 months amounting to 0.43. The Price to Book ratio for the last quarter was 0.65, with the Price to Cash per share for the same quarter was set at 0.56. Price to Free Cash Flow for CX in the course of the last twelve months was 3.24 with Quick ratio for the last quarter at 0.60.

CX stock trade performance evaluation

CEMEX S.A.B. de C.V. [CX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.06. With this latest performance, CX shares gained by 17.27% in over the last four-week period, additionally sinking by -15.90% over the last 6 months – not to mention a drop of -43.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CX stock in for the last two-week period is set at 64.23, with the RSI for the last a single of trading hit 66.04, and the three-weeks RSI is set at 60.96 for CEMEX S.A.B. de C.V. [CX]. The present Moving Average for the last 50 days of trading for this stock 4.00, while it was recorded at 4.56 for the last single week of trading, and 5.14 for the last 200 days.

CEMEX S.A.B. de C.V. [CX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and CEMEX S.A.B. de C.V. [CX] shares currently have an operating margin of +11.92 and a Gross Margin at +30.81. CEMEX S.A.B. de C.V.’s Net Margin is presently recorded at +5.24.

Return on Equity for this stock inclined to 8.55, with Return on Assets sitting at 2.78.

CEMEX S.A.B. de C.V.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.90.

Earnings per share (EPS) analysis for CEMEX S.A.B. de C.V. [CX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CEMEX S.A.B. de C.V. go to 33.20%.

CEMEX S.A.B. de C.V. [CX]: Insider Ownership positions

There are presently around $1,977 million, or 32.30% of CX stock, in the hands of institutional investors. The top three institutional holders of CX stocks are: BAILLIE GIFFORD & CO with ownership of 74,960,455, which is approximately 20.254% of the company’s market cap and around 60.00% of the total institutional ownership; FMR LLC, holding 71,539,934 shares of the stock with an approximate value of $325.51 million in CX stocks shares; and BRANDES INVESTMENT PARTNERS, LP, currently with $155.47 million in CX stock with ownership of nearly 9.168% of the company’s market capitalization.

Positions in CEMEX S.A.B. de C.V. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 93 institutional holders increased their position in CEMEX S.A.B. de C.V. [NYSE:CX] by around 58,219,654 shares. Additionally, 123 investors decreased positions by around 72,662,945 shares, while 41 investors held positions by with 303,609,796 shares. The mentioned changes placed institutional holdings at 434,492,395 shares, according to the latest SEC report filing. CX stock had 25 new institutional investments in for a total of 7,340,501 shares, while 46 institutional investors sold positions of 26,049,430 shares during the same period.


Please enter your comment!
Please enter your name here